Publications by authors named "Marc Ladanyi"

100Publications

CNS Metastases in Patients With Exon 14-Altered Lung Cancers and Outcomes With Crizotinib.

JCO Precis Oncol 2020 27;4. Epub 2020 Jul 27.

Thoracic Oncology and Early Drug Development Services, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center; and Weill Cornell Medical College, New York, NY.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/PO.20.00098DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7446485PMC
July 2020

Characterization of TP53-wildtype tubo-ovarian high-grade serous carcinomas: rare exceptions to the binary classification of ovarian serous carcinoma.

Mod Pathol 2020 Aug 15. Epub 2020 Aug 15.

Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, United States.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41379-020-00648-yDOI Listing
August 2020

The epigenomics of sarcoma.

Nat Rev Cancer 2020 Oct 11;20(10):608-623. Epub 2020 Aug 11.

Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, British Columbia, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41568-020-0288-4DOI Listing
October 2020

Precision medicine in non-small cell lung cancer: Current applications and future directions.

Semin Cancer Biol 2020 Jul 27. Epub 2020 Jul 27.

University Hospital of Cologne, Department of Pathology, Germany. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.semcancer.2020.07.009DOI Listing
July 2020

[Ⅱ.MSK-IMPACT of Bone and Soft Tissue Sarcomas in Japan].

Gan To Kagaku Ryoho 2020 Mar;47(3):428-435

Dept. of Orthopedic Surgery, Juntendo University School of Medicine.

View Article

Download full-text PDF

Source
March 2020

Development, Validation, and Regulatory Considerations for a Liquid Biopsy Test.

Clin Chem 2020 Mar;66(3):408-414

Chief, Molecular Diagnostics Service, Department of Pathology, Memorial Sloan Kettering Cancer Center.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/clinchem/hvaa010DOI Listing
March 2020

Infarction with associated pseudosarcomatous changes mimics anaplasia in otherwise grade I meningiomas.

Mod Pathol 2020 07 11;33(7):1298-1306. Epub 2020 Feb 11.

Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41379-020-0491-6DOI Listing
July 2020

BCOR Expression in Mullerian Adenosarcoma: A Potential Diagnostic Pitfall.

Am J Surg Pathol 2020 Jun;44(6):765-770

Department of Pathology, Memorial Sloan Kettering Cancer Center, New York City, NY.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/PAS.0000000000001445DOI Listing
June 2020

Novel Germline Mutations in DNA Damage Repair in Patients with Malignant Pleural Mesotheliomas.

J Thorac Oncol 2020 04 28;15(4):655-660. Epub 2019 Dec 28.

Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York; Department of Medicine, Weill Cornell Medicine, New York, New York. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jtho.2019.12.111DOI Listing
April 2020

RUNX2 (6p21.1) amplification in osteosarcoma.

Hum Pathol 2019 12 25;94:23-28. Epub 2019 Oct 25.

Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA, 10065. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.humpath.2019.09.010DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7053429PMC
December 2019

Histone H3K36I mutation in a metastatic histiocytic tumor of the skull and response to sarcoma chemotherapy.

Cold Spring Harb Mol Case Stud 2019 10 23;5(5). Epub 2019 Oct 23.

Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1101/mcs.a004606DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6824254PMC
October 2019

Concurrent RB1 and TP53 Alterations Define a Subset of EGFR-Mutant Lung Cancers at risk for Histologic Transformation and Inferior Clinical Outcomes.

J Thorac Oncol 2019 10 19;14(10):1784-1793. Epub 2019 Jun 19.

Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York; Weill Cornell Medical College, New York, New York. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jtho.2019.06.002DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6764905PMC
October 2019

Loss of BAP1 as a candidate predictive biomarker for immunotherapy of mesothelioma.

Genome Med 2019 03 26;11(1):18. Epub 2019 Mar 26.

Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY, 10065, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s13073-019-0631-0DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6436227PMC
March 2019

Acquired BRAF Rearrangements Induce Secondary Resistance to EGFR therapy in EGFR-Mutated Lung Cancers.

J Thorac Oncol 2019 05 1;14(5):802-815. Epub 2019 Mar 1.

Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jtho.2018.12.038DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6486868PMC
May 2019

Fusion oncogenes-genetic musical chairs.

Science 2018 08;361(6405):848-849

Department of Pathology and Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.

View Article

Download full-text PDF

Source
http://www.sciencemag.org/lookup/doi/10.1126/science.aau8231
Publisher Site
http://dx.doi.org/10.1126/science.aau8231DOI Listing
August 2018

Tumor Mutation Burden and Efficacy of EGFR-Tyrosine Kinase Inhibitors in Patients with -Mutant Lung Cancers.

Clin Cancer Res 2019 02 25;25(3):1063-1069. Epub 2018 Jul 25.

Department of Medicine, Division of Solid Tumor Oncology, Thoracic Oncology Service, Memorial Sloan Kettering Cancer Center, New York, New York.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-18-1102DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6347551PMC
February 2019

The SS18-SSX Oncoprotein Hijacks KDM2B-PRC1.1 to Drive Synovial Sarcoma.

Cancer Cell 2018 03 1;33(3):527-541.e8. Epub 2018 Mar 1.

Cancer Biology and Genetics Program, Memorial Sloan-Kettering Cancer Center, New York, NY 10065, USA; Howard Hughes Medical Institute, New York, NY 10065, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ccell.2018.01.018DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5881394PMC
March 2018

Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children.

N Engl J Med 2018 02;378(8):731-739

From Memorial Sloan Kettering Cancer Center (A. Drilon, J.F.H., R.B., M.L., D.M.H.) and Weill Cornell Medical College (A. Drilon, D.M.H.), New York; University of Texas Southwestern Medical Center-Children's Health, Dallas (T.W.L.); Stanford Cancer Center, Stanford University, Palo Alto (S.K.), Children's Hospital Los Angeles, Keck School of Medicine, University of Southern California (L.M.), and UCLA David Geffen School of Medicine (N.F.), Los Angeles, and Loxo Oncology, South San Francisco (B.B.T., K.E., S.C., N.C.K., M.C.C.) - all in California; Dana-Farber-Boston Children's Cancer and Blood Disorders Center (S.G.D.), Dana-Farber Cancer Institute (G.D.D., M.N.), Ludwig Center at Harvard (G.D.D.), and Massachusetts General Hospital (A.F.F.) - all in Boston; the Finsen Center, Rigshospitalet, Copenhagen (U.N.L.); University of Colorado, Aurora (R.C.D.); St. Jude Children's Research Hospital, Memphis (A.S.P.), and Vanderbilt University, Nashville (J.B.) - both in Tennessee; Cincinnati Children's Hospital Medical Center, Cincinnati (B.T.); University Hospitals of Cleveland Medical Center (A. Dowlati) and Taussig Cancer Institute, Cleveland Clinic (D.P.S.S.), Cleveland; University of Pennsylvania Perelman School of Medicine, Department of Otorhinolaryngology and Head and Neck Surgery, and the Abramson Cancer Center (M.S.B.), and Fox Chase Cancer Center (W.S.E.-D.), Philadelphia; University of Washington-Seattle Cancer Care Alliance (C.B.), Seattle Children's Hospital (E.R.R.), and Seattle Children's Hospital, University of Washington, Fred Hutchinson Cancer Research Center (D.S. Hawkins), Seattle; University of Texas M.D. Anderson Cancer Center, Houston (F.M.-B., D.S. Hong); Inova Schar Cancer Institute, Falls Church, VA (J.D.); START Madrid, Centro Integral Oncológico Clara Campal, Madrid (V.B.); Nemours Children's Hospital, Orlando (R.N.), and Memorial Cancer Institute-Florida International University, Miami (L.E.R.) - both in Florida; Oregon Health and Science University, Portland (M.T.); and WVU Cancer Institute, West Virginia University, Morgantown (P.C.M.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1714448DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5857389PMC
February 2018

The molecular pathology of cancer: from pan-genomics to post-genomics.

J Pathol 2018 04;244(5):509-511

Department of Pathology and Human Oncology & Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/path.5057DOI Listing
April 2018

Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors: Guideline From the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology.

Arch Pathol Lab Med 2018 Mar 22;142(3):321-346. Epub 2018 Jan 22.

From the Departments of Pathology (Drs Lindeman and Sholl) and Medicine (Dr Kwiatkowski), Brigham and Women's Hospital, Boston, Massachusetts; the Cancer Center (Dr Bernicker) and the Department of Pathology and Genomic Medicine, Houston Methodist Hospital, Houston, Texas (Dr Cagle); the Department of Pathology, University of Colorado School of Medicine, Denver (Dr Aisner); the Diagnostic and Molecular Pathology Laboratory (Dr Arcila) and the Molecular Diagnostics Service (Dr Ladanyi), Memorial Sloan Kettering Cancer Center, New York, New York; the Department of Pathology & Medicine, Pulmonary, Critical Care and Sleep Medicine, New York, New York (Dr Beasley); the Pathology and Laboratory Quality Center, College of American Pathologists, Northfield, Illinois (Mss Colasacco and Ventura); the Department of Pathology, University of Pittsburgh, Pittsburgh, Pennsylvania (Dr Dacic); the Department of Medicine and Pathology, University of Colorado, Denver (Dr Hirsch); the Department of Pathology, University of Aberdeen, Aberdeen, Scotland (Dr Kerr); the Department of Molecular Pathology, Roswell Park Cancer Institute, Buffalo, New York (Dr Nowak); the Clinical and Scientific Affairs Division, Association for Molecular Pathology, Bethesda, Maryland (Dr Temple-Smolkin); the Molecular Therapeutics and Biomarkers Laboratory, Peter Maccallum Cancer Center, Melbourne, Australia (Dr Solomon); the Department of Pathology, VU University Medical Center, Amsterdam, the Netherlands (Dr Thunnissen); the Department of Laboratory Medicine and Pathobiology, Princess Margaret Cancer Center, Toronto, Ontario, Canada (Dr Tsao); Scientific Affairs, International Association for the Study of Lung Cancer, Aurora, Colorado (Dr Wynes); and the Department of Pathology and Molecular Diagnostics, Aichi Cancer Center, Nagoya, Japan (Dr Yatabe). Dr Souter is in private practice in Wellanport, Ontario, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.5858/arpa.2017-0388-CPDOI Listing
March 2018

Molecular Determinants of Response to Anti-Programmed Cell Death (PD)-1 and Anti-Programmed Death-Ligand 1 (PD-L1) Blockade in Patients With Non-Small-Cell Lung Cancer Profiled With Targeted Next-Generation Sequencing.

J Clin Oncol 2018 03 16;36(7):633-641. Epub 2018 Jan 16.

Hira Rizvi, Francisco Sanchez-Vega, Konnor La, Walid Chatila, Philip Jonsson, Darragh Halpenny, Andrew Plodkowski, Niamh Long, Jennifer L. Sauter, Natasha Rekhtman, Travis Hollmann, Ronglai Shen, Ai Ni, Kathryn C. Arbour, Taha Merghoub, Jedd Wolchok, Jamie E. Chaft, Mark G. Kris, Charles M. Rudin, Nicholas D. Socci, Michael F. Berger, Barry S. Taylor, Ahmet Zehir, David B. Solit, Maria E. Arcila, Marc Ladanyi, Gregory J. Riely, Nikolaus Schultz, and Matthew D. Hellmann, Memorial Sloan Kettering Cancer Center; Taha Merghoub, Jedd Wolchok, Alexandra Snyder, Jamie E. Chaft, Mark G. Kris, Charles M. Rudin, Gregory J. Riely, and Matthew D. Hellmann, Weill Cornell Medical College, New York, NY; Kurt A. Schalper, Yale School of Medicine, New Haven, CT; Justin F. Gainor, Massachusetts General Hospital, Boston, MA; and Alexandra Snyder, Adaptive Biotechnologies, Seattle, WA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2017.75.3384DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6075848PMC
March 2018

Clinical Sequencing Defines the Genomic Landscape of Metastatic Colorectal Cancer.

Cancer Cell 2018 01;33(1):125-136.e3

Marie-Josée and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA; Departments of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ccell.2017.12.004DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5765991PMC
January 2018